Volume 102, Issue 5 pp. 966-967
COMMENTARY

Stenting of coarctation of the aorta—“Once and for all?”

Athar M. Qureshi MD

Corresponding Author

Athar M. Qureshi MD

Department of Pediatrics, The Lillie Frank Abercrombie Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA

Correspondence Athar M. Qureshi, MD, CE Mullins Cardiac Catheterization Laboratories, The Lillie Frank Abercrombie Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Baylor St. Luke's Medical Center, 6651 Main Street, E 1920, Houston, TX 77030, USA.

Email: [email protected]

Search for more papers by this author
Shakeel A. Qureshi MBChB, FRCP

Shakeel A. Qureshi MBChB, FRCP

Department of Paediatric and Adult Congenital Heart Disease, Evelina London Children's Hospital, Guy's and St. Thomas’ NHS Foundation Trust, London, UK

Search for more papers by this author
First published: 30 October 2023

Expert Article Analysis for: Long-term follow-up after endovascular treatment of aortic coarctation with bare and covered Cheatham platinum stents

Key Points

  • Long term hemodynamic benefit and survival are sustained in patients undergoing stenting of coarctation of the aorta with bare metal and covered Cheatham-Platinum (CP) stents.

  • Reintervention and complication rates are similar with both bare metal and covered CP stents.

  • Routine advanced imaging should be performed periodically in the long-term to assess for stent integrity and aortic wall injury, and to guide treatment/reintervention, when necessary.

CONFLICT OF INTEREST STATEMENT

Athar M. Qureshi, MD, is a consultant for Medtronic, W.L Gore and Associates, and Abiomed Inc. Shakeel A Qureshi, MBChB, is a Consultant for NuMED Inc., Occlutech, Medtronic, Lifetech and Venus Medtech.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.